0% found this document useful (0 votes)
39 views14 pages

Ayomide 22

Optics and waves

Uploaded by

ayoolad30
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PPTX, PDF, TXT or read online on Scribd
0% found this document useful (0 votes)
39 views14 pages

Ayomide 22

Optics and waves

Uploaded by

ayoolad30
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PPTX, PDF, TXT or read online on Scribd

SEMINAR PRESENTATION

DANGER AND USES OF ORAL CONTRACEPTIVE

BY
OYEBODE-OMOLE AYOMIDE
2122/MLT/356

SUBMITTED TO THE DEPARTMENT OF MEDICAL LABORATORY


TECHNICIAN, MILLENNIUM COLLEGE OF HEALTH TECHNOLOGY AKURE,
ONDO STATE
01/25/2025 1
OUTLINES
• INTRODUCTION
• ORAL CONTRACEPTIVES
• COMBINED ORAL CONTRACEPTIVE (COC)
• MECHANISM OF ACTION
• USES OF ORAL CONTRACEPTIVES
• DANGERS OF ORAL CONTRACEPTIVES
• CONCLUSION
• RECOMMENDATION

01/25/2025 2
INTRODUCTION

• Oral contraceptives are hormone-containing medications that are


taken by mouth to prevent pregnancy.
• They prevent pregnancy by inhibiting ovulation and also by preventing
sperm from penetrating through the cervix.
• Several studies have provided consistent evidence that the risks of
breast and cervical cancers are increased in women who use oral
contraceptives (Vecchia et al., 2019).

01/25/2025 3
ORAL CONTRACEPTIVES
• According to United Nations estimates, oral contraceptives are
currently used by nearly 62 million women (United Nations, 1989).

• Two types of oral contraceptives (OCs) are available:

Combination Oral Contraceptives, consisting of the hormones


estrogen and progestin.

Progestin-only pill (often called the minipill). (Trussell and Kost, 1987).

01/25/2025 4
COMBINED ORAL CONTRACEPTIVE
• The combination is prescribed based on desirable effects and risk of
adverse events with progestin component and dose of estrogen and
progestin component. (Maguire et al., 2011).

• Estrogen component: Estradiol, Ethinylestradiol, or Estetrol

• First-generation progestin: Norethindrone acetate, Ethynodiol


diacetate, Lynestrenol, Norethynodrel

01/25/2025 5
MECHANISM OF ACTION
• Progesterone is primarily responsible for preventing pregnancy.

• The main mechanism of action is the prevention of ovulation; they


inhibit follicular development and prevent ovulation.

• The progestogen negative feedback and lack of estrogen positive


feedback on LH secretion stop the mid-cycle LH surge.

• With no follicle developed and no LH surge to release the follicle,


ovulation is prevented
01/25/2025 6
• Estrogen has some effect with inhibiting follicular development
because of its negative feedback on the anterior pituitary with slowed
FSH secretion;

• it’s just not as prominent as the progesterone’s effect.

01/25/2025 7
USES OF ORAL CONTRACEPTIVES
• They are used to reduce rate of unintended Pregnancies
• They are used to reduce the need for unsafe abortion
• They also reduce HIV transmissions from mother to newborn

01/25/2025 8
DANGERS OF USING ORAL CONTRACEPTIVES

• Most side effects of OCP's are mild and disappear with continued use or
switching to another pill formulation.

• The most common adverse effect of combined oral contraceptive pills is


breakthrough bleeding. (Tayob et al., 2015).

• Women will also complain of nausea, headaches, abdominal cramping,


breast tenderness, and increased vaginal discharge or decreased libido.
(Nylander et al., 2014).
01/25/2025 9
DANGERS OF USING ORAL CONTRACEPTIVES

• Nausea can be avoided by taking the medication at night before sleep.

• The majority of the other consequences will resolve with time or


switching OCP to a different preparation.

• Oral contraceptive pills can cause hypertension in 4-5% of healthy


women and exacerbate hypertension in about 9-16% of women with
pre-existing hypertension. (Nylander et al., 2014).

01/25/2025 10
CONCLUSION

• Preventive medicine is the backbone of any medical system. Patients


must have confidence that the measures physicians are
recommending are going to be beneficial for their health.

• Oral contraceptives increase rates of cardiovascular morbidity and


mortality, as well as increasing the rates of breast and cervical
cancers.

01/25/2025 11
RECOMMENDATION

• Patients need complete informed consent on all of the possible risks of


OCPs.
• Complete personal and family histories need to be ascertained by health-
care providers to ensure that adverse events do not occur.

• Patients do incur health risks when choosing oral contraceptives.

• They should not be misled or confused into believing that what they are
taking is “good for them”
• Has similar beneficial effects to other evidence-based preventive measures.
01/25/2025 12
REFERENCES
• ACOG Practice Bulletin No. 110: noncontraceptive uses of hormonal contraceptives. Obstet Gynecol. 2010 Jan;115(1):206-218. [PubMed]
• Arowojolu AO, Gallo MF, Lopez LM, Grimes DA, Garner SE. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst
Rev. 2019 Jul 08;(3):CD004425. [PubMed]
• se, 2016. MMWR Recomm Rep. 2016 Jul 29;65(4):1-66. [PubMed]
• Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, Simmons KB, Pagano HP, Jamieson DJ, Whiteman MK. U.S. Medical
Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep. 2016 Jul 29;65(3):1-103. [PubMed]
• Estetrol/drospirenone (Nextstellis) - a new combination oral contraceptive. Med Lett Drugs Ther. 2021 Jun 28;63(1627):101-102. [PubMed]
• Kapp N, Curtis KM. Combined oral contraceptive use among breastfeeding women: a systematic review. Contraception. 2010 Jul;82(1):10-6. [
PubMed]
• Korver T, Goorissen E, Guillebaud J. The combined oral contraceptive pill: what advice should we give when tablets are missed? Br J Obstet
Gynaecol. 2015 Aug;102(8):601-7. [PubMed]
• Maguire K, Westhoff C. The state of hormonal contraception today: established and emerging noncontraceptive health benefits. Am J Obstet
Gynecol. 2011 Oct;205(4 Suppl):S4-8. [PubMed]
• McCarthy KJ, Gollub EL, Ralph L, van de Wijgert J, Jones HE. Hormonal Contraceptives and the Acquisition of Sexually Transmitted Infections:
An Updated Systematic Review. Sex Transm Dis. 2019 May;46(5):290-296. [PubMed]
• Simmons KB, Haddad LB, Nanda K, Curtis KM. Drug interactions between non-rifamycin antibiotics and hormonal contraception: a systematic
review. Am J Obstet Gynecol. 2018 Jan;218(1):88-97.e14. [PubMed]
• Tayob Y, Adams J, Jacobs HS, Guillebaud J. Ultrasound demonstration of increased frequency of functional ovarian cysts in women using
progestogen-only oral contraception. Br J Obstet Gynaecol. 2015 Oct;92(10):1003-9. [PubMed]

01/25/2025 13
THANKS FOR
LISTENING

01/25/2025 14

You might also like